| Sep 30 |
Is Genmab A/S (GMAB) One of the Best Revenue Growth Stocks to Buy According to Analysts?
|
| Sep 26 |
Grant of Restricted Stock Units and Warrants to Employees in Genmab
|
| Sep 15 |
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
|
| Aug 30 |
Genmab A/S (GMAB): One of the Best Affordable Stocks Under $40 According to Short Sellers
|
| Aug 28 |
Top High Growth Tech Stocks To Watch In August 2024
|
| Aug 26 |
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
|
| Aug 23 |
Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab
|
| Aug 20 |
AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use
|
| Aug 19 |
AbbVie, Genmab receive European approval for Tepkinly in follicular lymphoma
|
| Aug 19 |
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
|
